Suciraslimab

舒西利单抗

Report date: 2026/03/09 14:49:57

Base Information

Drug NameSuciraslimab
Drug Alias NameRecombinant anti-CD22 antibody (Lonn Ryonn Pharma)重组人CD22单抗（深圳龙瑞药业）Recombinant anti-CD22 monoclonal antibody (Lonn Ryonn Pharma)SM-03SM-06
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsPemphigoid, BullousLupus Erythematosus, SystemicArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLonn Ryonn Pharma LtdSinomab Bioscience Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhong Anti-Bio Pharmaceutical (Haikou) Co LtdLonn Ryonn Pharma Ltd
Inactive CompaniesSinomab Bioscience Ltd
Active IndicationsPemphigoid, BullousArthritis, Rheumatoid
Inactive IndicationsLupus Erythematosus, SystemicLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A